1 Trastuzumab Biosimilar Market Overview

• 1.1 Product Overview and Scope of Trastuzumab Biosimilar
• 1.2 Trastuzumab Biosimilar Segment by Type
  • 1.2.1 Global Trastuzumab Biosimilar Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Adjuvant Breast Cancer
  • 1.2.3 Metastatic Breast Cancer
  • 1.2.4 Metastatic Gastric Cancer
  • 1.2.5 Others
• 1.3 Trastuzumab Biosimilar Segment by Application
  • 1.3.1 Trastuzumab Biosimilar Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Online Pharmacy
• 1.4 Global Trastuzumab Biosimilar Market Size Estimates and Forecasts
  • 1.4.1 Global Trastuzumab Biosimilar Revenue 2016-2027
  • 1.4.2 Global Trastuzumab Biosimilar Sales 2016-2027
  • 1.4.3 Trastuzumab Biosimilar Market Size by Region: 2016 Versus 2021 Versus 2027

2 Trastuzumab Biosimilar Market Competition by Manufacturers

• 2.1 Global Trastuzumab Biosimilar Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Trastuzumab Biosimilar Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Trastuzumab Biosimilar Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Trastuzumab Biosimilar Manufacturing Sites, Area Served, Product Type
• 2.5 Trastuzumab Biosimilar Market Competitive Situation and Trends
  • 2.5.1 Trastuzumab Biosimilar Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Trastuzumab Biosimilar Players Market Share by Revenue
  • 2.5.3 Global Trastuzumab Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Trastuzumab Biosimilar Retrospective Market Scenario by Region

• 3.1 Global Trastuzumab Biosimilar Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Trastuzumab Biosimilar Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Trastuzumab Biosimilar Market Facts & Figures by Country
  • 3.3.1 North America Trastuzumab Biosimilar Sales by Country
  • 3.3.2 North America Trastuzumab Biosimilar Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Trastuzumab Biosimilar Market Facts & Figures by Country
  • 3.4.1 Europe Trastuzumab Biosimilar Sales by Country
  • 3.4.2 Europe Trastuzumab Biosimilar Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Trastuzumab Biosimilar Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Trastuzumab Biosimilar Sales by Region
  • 3.5.2 Asia Pacific Trastuzumab Biosimilar Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Trastuzumab Biosimilar Market Facts & Figures by Country
  • 3.6.1 Latin America Trastuzumab Biosimilar Sales by Country
  • 3.6.2 Latin America Trastuzumab Biosimilar Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Trastuzumab Biosimilar Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Trastuzumab Biosimilar Sales by Country
  • 3.7.2 Middle East and Africa Trastuzumab Biosimilar Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Trastuzumab Biosimilar Historic Market Analysis by Type

• 4.1 Global Trastuzumab Biosimilar Sales Market Share by Type (2016-2021)
• 4.2 Global Trastuzumab Biosimilar Revenue Market Share by Type (2016-2021)
• 4.3 Global Trastuzumab Biosimilar Price by Type (2016-2021)

5 Global Trastuzumab Biosimilar Historic Market Analysis by Application

• 5.1 Global Trastuzumab Biosimilar Sales Market Share by Application (2016-2021)
• 5.2 Global Trastuzumab Biosimilar Revenue Market Share by Application (2016-2021)
• 5.3 Global Trastuzumab Biosimilar Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 Amgen Inc.
  • 6.1.1 Amgen Inc. Corporation Information
  • 6.1.2 Amgen Inc. Description and Business Overview
  • 6.1.3 Amgen Inc. Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 Amgen Inc. Product Portfolio
  • 6.1.5 Amgen Inc. Recent Developments/Updates
• 6.2 Pfizer Inc
  • 6.2.1 Pfizer Inc Corporation Information
  • 6.2.2 Pfizer Inc Description and Business Overview
  • 6.2.3 Pfizer Inc Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Pfizer Inc Product Portfolio
  • 6.2.5 Pfizer Inc Recent Developments/Updates
• 6.3 Samsung Bioepis
  • 6.3.1 Samsung Bioepis Corporation Information
  • 6.3.2 Samsung Bioepis Description and Business Overview
  • 6.3.3 Samsung Bioepis Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Samsung Bioepis Product Portfolio
  • 6.3.5 Samsung Bioepis Recent Developments/Updates
• 6.4 Merck & Co.
  • 6.4.1 Merck & Co. Corporation Information
  • 6.4.2 Merck & Co. Description and Business Overview
  • 6.4.3 Merck & Co. Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Merck & Co. Product Portfolio
  • 6.4.5 Merck & Co. Recent Developments/Updates
• 6.5 Biocon Limited
  • 6.5.1 Biocon Limited Corporation Information
  • 6.5.2 Biocon Limited Description and Business Overview
  • 6.5.3 Biocon Limited Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Biocon Limited Product Portfolio
  • 6.5.5 Biocon Limited Recent Developments/Updates
• 6.6 Teva Pharmaceutical
  • 6.6.1 Teva Pharmaceutical Corporation Information
  • 6.6.2 Teva Pharmaceutical Description and Business Overview
  • 6.6.3 Teva Pharmaceutical Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Teva Pharmaceutical Product Portfolio
  • 6.6.5 Teva Pharmaceutical Recent Developments/Updates
• 6.7 Genentech
  • 6.6.1 Genentech Corporation Information
  • 6.6.2 Genentech Description and Business Overview
  • 6.6.3 Genentech Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Genentech Product Portfolio
  • 6.7.5 Genentech Recent Developments/Updates
• 6.8 Mundipharma
  • 6.8.1 Mundipharma Corporation Information
  • 6.8.2 Mundipharma Description and Business Overview
  • 6.8.3 Mundipharma Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Mundipharma Product Portfolio
  • 6.8.5 Mundipharma Recent Developments/Updates
• 6.9 Celltrion
  • 6.9.1 Celltrion Corporation Information
  • 6.9.2 Celltrion Description and Business Overview
  • 6.9.3 Celltrion Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Celltrion Product Portfolio
  • 6.9.5 Celltrion Recent Developments/Updates
• 6.10 Henlius
  • 6.10.1 Henlius Corporation Information
  • 6.10.2 Henlius Description and Business Overview
  • 6.10.3 Henlius Trastuzumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Henlius Product Portfolio
  • 6.10.5 Henlius Recent Developments/Updates

7 Trastuzumab Biosimilar Manufacturing Cost Analysis

• 7.1 Trastuzumab Biosimilar Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Trastuzumab Biosimilar
• 7.4 Trastuzumab Biosimilar Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Trastuzumab Biosimilar Distributors List
• 8.3 Trastuzumab Biosimilar Customers

9 Trastuzumab Biosimilar Market Dynamics

• 9.1 Trastuzumab Biosimilar Industry Trends
• 9.2 Trastuzumab Biosimilar Growth Drivers
• 9.3 Trastuzumab Biosimilar Market Challenges
• 9.4 Trastuzumab Biosimilar Market Restraints

10 Global Market Forecast

• 10.1 Trastuzumab Biosimilar Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Trastuzumab Biosimilar by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Trastuzumab Biosimilar by Type (2022-2027)
• 10.2 Trastuzumab Biosimilar Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Trastuzumab Biosimilar by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Trastuzumab Biosimilar by Application (2022-2027)
• 10.3 Trastuzumab Biosimilar Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Trastuzumab Biosimilar by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Trastuzumab Biosimilar by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Adjuvant Breast Cancer
Metastatic Breast Cancer
Metastatic Gastric Cancer
Others

Segment by Application
Hospital Pharmacy
Online Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Amgen Inc.
Pfizer Inc
Samsung Bioepis
Merck & Co.
Biocon Limited
Teva Pharmaceutical
Genentech
Mundipharma
Celltrion
Henlius